Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Eisai Files First Products in South Africa



                  Eisai Files First Products in South Africa

  PR Newswire

  HATFIELD, England, January 29, 2013

HATFIELD, England, January 29, 2013 /PRNewswire/ --

            Expansion into Africa with the filing of two products

Eisai announces the expansion of its operations into South Africa, with the
filing of its two products - Halaven® (eribulin) for metastatic breast cancer
and Fycompa® (perampanel) for epilepsy to The Medicines Control Council (MCC).

The South African government has set out plans to introduce a universal
healthcare system with the public health budget growing considerably. ^[1] The
South African pharmaceutical market is also expected to double in the next six
years. ^[2] Eisai's continued growth is part of the company's Hayabusa plan to
have a presence in the top 20 pharmaceutical markets and deliver effective
treatments to more than 500 million patients by 2015.

"Eisai has been successfully operating in Europe for more than 20 years and we
are proud to be bringing effective medicines to countries outside this
region," said Gary Hendler, President and CEO of Eisai Europe, Middle East,
Africa and Russian (EMEA) business. "The filing of Halaven and Fycompa in
South Africa shows our commitment to our expansion plans to provide effective
treatments to more patients around the world. This also further validates our
human health care (hhc) mission to satisfy unmet medical needs and contribute
to the health and well-being of people worldwide."

In South Africa an estimated 8,000 South African women are diagnosed with
breast cancer every year and it is predicted that 20% will die from the
disease. ^[3] The filing of eribulin in South Africa is a step closer to
giving women with metastatic breast cancer access to a treatment with proven
significant overall survival benefit compared to other single agent
chemotherapies, as demonstrated by the EMBRACE Study. ^[4] The filing of
eribulin in South Africa is based on data obtained from the EMBRACE Study.
Since the launch of eribulin in Europe, it has given heavily pre-treated women
with metastatic breast cancer precious additional time with their loved ones.

Discovered and manufactured by Eisai, perampanel has been approved by the
European Commission (EC) and is now available in the UK, Germany, Austria,
Denmark, Sweden and Norway as an adjunctive therapy for patients with
partial-onset seizures (the most common form of epilepsy) aged 12 years and
above. Eisai expects the availability of perampanel in South Africa in will be
a significant step for people with epilepsy, as successful control of
partial-onset seizures remains a challenge. An estimated 1 in 100 people have
epilepsy in South Africa. ^[5]

                               Notes to Editors

About Eisai's Commitment to Improving Global Access to Medicines

Today, it is estimated that some 2.7 billion* people around the world live on
US$2 or less per day. Most of these 2.7 billion people do not have access to
essential health care and treatment despite the availability of effective
medicines. This is an international challenge that needs to be solved through
collaborations among governments, international organisations such as the WHO,
non-governmental organisations and pharmaceutical companies.

In line with its human health care (hhc) mission, Eisai is committed to
improving global access to medicines over the medium-to-long term through
partnership strategies that involve working with governments, international
organisations, private entities and non-profit organisations. Specifically,
the company has developed and is implementing a five-target approach to
improve access to medicines worldwide. The five key components are: product
creations, strategic solutions, capacity building, quality innovation, and
long-term investment.

For further information on Eisai's Access to Medicines initiatives, please
visit the Access to Medicines page on the Eisai Global website:
http://www.eisai.com/company/atm/index.html

* Source: World Bank (2005)

About Eisai Eisai is one of the world's leading research and development (R&D)
based pharmaceutical companies and we define our corporate mission as "giving
first thought to patients and their families and to increasing the benefits
health care provides," which we call human health care ( hhc ). Eisai
concentrates its R&D activities in three key areas:

  * Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
    loss
  * Oncology including: anticancer therapies; tumour regression, tumour
    suppression, antibodies, etc
  * Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
    arthritis, psoriasis, and inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of
Japan, Eisai employs more than 11,000 people worldwide. From its Europe based
Knowledge Centre in Hatfield, UK, Eisai has recently expanded business
operations to include the expanded territory of Europe, the Middle East,
Africa and Russia (EMEA). Eisai EMEA undertakes sales and marketing operations
in over 20 markets, including the United Kingdom, France, Germany, Italy,
Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway,
Portugal, Iceland, Czech Republic, Slovakia, the Netherlands, Belgium,
Luxembourg, the Middle East and Russia. For further information please visit:
http://www.eisai.com

1. http://www.bbc.co.uk/news/world-africa-14504628  (Last accessed Nov 2012)

2.
http://www.africanbusinessreview.co.za/money_matters/south-africas-pharmaceutical-market-booms

3. BATEMAN, Chris. Breast cancer breakthrough in gene profilings?. SAMJ, S.
Afr. med. j. [online]. 2009, vol.99, n.11, pp. 780-782.
http://www.scielo.org.za/scielo.php?pid=S0256-95742009001100009&script=sci_arttext
 (Last accessed Nov 2012)

4. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus
treatment of physician's choice in patients with metastatic breast cancer
(EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011; 377: 914
-923

5. http://www.epilepsy.org.za/epsa/faq.php#what [
http://www.epilepsy.org.za/epsa/faq.php ] (Last accessed Nov 2012)

 

Corporate-UK2009

January 2012

Contact: Media Enquiries: Eisai Europe Ltd, Charlotte Andrews / Cressida
Robson, +44(0)7908-314-155/ +44(0)7947-231-513, Cressida_Robson@eisai.net,
charlotte_andrews@eisai.net; Tonic Life Communications, Benjamyn Tan/ April
Kenneally, +44(0)20-7798-9999 / +44(0)207-798-9263, benjamyn.tan@toniclc.com,
eisaiepilepsy@toniclc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement